A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma Meeting Abstract
| Authors: | Konner, J. A.; Boucicaut, N. N.; O'Cearbhaill, R. E.; Zamarin, D.; Makker, V.; Sabbatini, P.; Tew, W. P.; Cadoo, K. A.; Grisham, R. N.; Aghajanian, C. |
| Abstract Title: | A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 304s |
| Language: | English |
| ACCESSION: | WOS:000411931704050 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.5572 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 5572 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
263Makker -
155Konner -
201Zamarin -
262Sabbatini -
169Grisham -
271O'Cearbhaill -
607Aghajanian -
244Tew -
113Cadoo
Related MSK Work